Universities and healthcare institutions in Texas and Colorado are involved in promising, cutting-edge biomedical research. Much of this research is considered too early stage to attract the financial and business support of experienced entrepreneurs and established venture capital companies. Remeditex was formed to invest in high quality, innovative, early stage projects that are judged to have commercialization potential. The goal is to help investigators establish the commercial viability of their research making it attractive to traditional investors.
Remeditex is not a classic venture capital fund or an additional source for basic scientific discovery funding. It is a company that will seek to develop opportunities in need of commercial validation, guidance, and capital.